HUBBARD, OH -- 11/03/09 --
NanoLogix, Inc. (PINKSHEETS: NNLX) announces
that the company has recently filed BNP™ (BioNanoPore) national patent
applications in China, Japan, India, Brazil, Russia and the EU. These
applications were filed in order to obtain intellectual property protection
for the company's technology in countries viewed as representing the
largest potential international market for BNP rapid detection, a
revolutionary sandwiched-membrane Petri-based technology that can reduce
microorganism detection times by 100-400%.
At the company's September 25th shareholder meeting, the support for all
proposals presented by the company for shareholder approval was
overwhelmingly positive, with all shareholder-rights/takeover-defense plan
proposals receiving 98-99% of the 64 million shares voted out of roughly
101 million shares outstanding.
The company has reclaimed full rights to 18 patents previously licensed to
Nutra Pharma Corporation after failure of Nutra Pharma to pay the balance
of patent royalties due for 2008 and the first half of 2009. Nutra Pharma
was served notice of their default in July. NanoLogix has returned the 18
patents to the company portfolio and will pursue development and marketing
of select technological aspects of the patents.
NanoLogix's April press release: "New Weapon in BioDefense Research:
NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague," was
highlighted in the latest issue of the Department of Defense Quarterly,
"CBRNIAC," from the Chemical, Biological, Radiological and Nuclear Defense
Information Analysis Center. The publication can be accessed at:
https://www.cbrniac.apgea.army.mil/Products/Newsletter/Pages/default.aspx
NanoLogix has received notification from New Brunswick Scientific of a
November 20th shipping date for ordered production equipment for its
cleanroom production facility at the company's Hubbard, Ohio headquarters.
This order consists of four machines for production of BNP rapid-detection
kits and is anticipated to be the first of many for kit production.
NanoLogix management, staff, and directors would like to congratulate
Corporate Counsel David R. Barnhizer for his recent three-year appointment
as Visiting Professor to the University of Westminster, London. Professor
Barnhizer will continue as corporate counsel.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on medical
diagnostics. Its products offer accelerated detection and identification of
microorganisms present in infectious and non-infectious human diseases. In
addition to medical, National Defense, and Homeland Security applications,
NanoLogix technology is applicable in pharmaceutical, industrial,
veterinary and environmental testing.
Patents pending or granted to NanoLogix can be used in the areas of applied
microbiology, soil microbiology and bioremediation, microbial physiology,
molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity,
stem-cell research, and bioreactor-based hydrogen generation.
More information on NanoLogix is available at: www.nanologix.com
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities Act of
1933 and the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations of
NanoLogix, Inc., and members of its management as well as the assumptions
on which such statements are based. Prospective investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual results
may differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or revise
forward-looking statements to reflect changed assumptions, the occurrence
of unanticipated events or changes to future operating results.
Contact:
NanoLogix, Inc.
Investor Relations
Carol Surrena
Telephone: 330-534-0800
E-mail: Email Contact
